

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmt.org/>

## Letter to the editor

# Beta-D-glucan assay as a tool for antifungal stewardship

Pooja Thakkar<sup>1,\*</sup>, Tanu Singhal<sup>2</sup>, Sweta Shah<sup>1</sup>, Shweta Ladi<sup>1</sup>

<sup>1</sup>Dept. of Microbiology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India

<sup>2</sup>Dept. of Hospital Infection Prevention and Control, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India



## ARTICLE INFO

### Article history:

Received 16-04-2023

Accepted 01-06-2023

Available online 18-07-2023

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

Implementation of antifungal stewardship (AFS) programs have the potential to reduce healthcare costs.<sup>1</sup> BDG assay has a high negative predictive value for invasive candidiasis (IC) and is thus an important tool for AFS.<sup>2</sup>

We conducted a study from January-December 2021 at a tertiary care hospital in Mumbai. A serum sample for BDG along with paired blood culture was sent for all patients before starting empirical echinocandin therapy. The BDG test was performed in house twice weekly using Fungitell@assay. The clinicians were advised to discontinue echinocandin if both BDG and cultures were negative. The patients in whom the echinocandin were stopped were monitored for IC during their hospital stay/day 28 whichever was earlier. The total cost saving was calculated considering an average of 10 day extra therapy with echinocandin and cost of the BDG test.

A total of 337 echinocandin prescriptions were made in 294 patients. BDG and blood cultures were sent before 292 of these prescriptions in 255 patients. The BDG as well as blood fungal cultures were negative in 53/292 prescriptions in 49 patients (15.7%). Compliance to recommendations for stopping echinocandin was 100%. None of these 49 patients had a sterile site culture positive for candida or deaths attributed to IC at end of follow up. Total cost savings were 6,794,440 INR during the study year as against the cost

of BDG assay 27, 59,400 INR

Our small study adds to published literature on AFS.<sup>3</sup> Apart from cost saving this strategy also has the potential for reducing echinocandin resistance. Non availability of BDG in most laboratories and long turnaround times is a major limitation to wider use of this strategy.<sup>4</sup> Finally, in light of a recent report of a false negative rate of 15% of BDG in patients with IC suggests that de-escalation should be done carefully in BDG negative patients.<sup>5</sup>

## Conflict of Interest

None.

## Source of Funding

None.

## References

1. Rautemaa-Richardson R, Rautemaa V, Al-Wathiqi F, Moore CB, Craig L, Felton TW, et al. Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. *J Antimicrob Chemother.* 2018;73(12):3488–95. doi:10.1093/jac/dky360.
2. Martin-Loeches I, Antonelli M, Cuenca-Estrella M. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. *Intensive Care Med.* 2019;45(6):789–805. doi:10.1007/s00134-019-05599-w.
3. Chakrabarti A, Mohamed N, Capparella MR, Townsend A, Sung AH, Yura R, et al. The Role of Diagnostics-Driven Antifungal Stewardship

\* Corresponding author.

E-mail address: [thakkarpooja@rediffmail.com](mailto:thakkarpooja@rediffmail.com) (P. Thakkar).

- in the Management of Invasive Fungal Infections: A Systematic Literature Review. *Open Forum Infect Dis.* 2022;9(7):ofac23. doi:10.1093/ofid/ofac234.
4. Chindamporn A, Chakrabarti A, Li R, Sun PL, Tan BH, Chua M, et al. Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: An Asia Fungal Working Group (AFWG) initiative. *Med Mycol.* 2018;56(4):29036605–29036605.
  5. Sridharan S, Gopalakrishnan R, Nambi PS, Kumar S, Sethuraman N, Ramasubramanian V, et al. Clinical Profile of Non-neutropenic Patients with Invasive Candidiasis: A Retrospective Study in a Tertiary Care Center. *Indian J Crit Care Med.* 2021;25(3):267–72.

## Author biography

**Pooja Thakkar**, Consultant Microbiology

**Tanu Singhal**, Consultant Paediatrics & Infectious Disease

**Sweta Shah**, Consultant Microbiology and Infection Prevention

**Shweta Ladi**, Technical Executive

**Cite this article:** Thakkar P, Singhal T, Shah S, Ladi S. Beta-D-glucan assay as a tool for antifungal stewardship. *IP Int J Med Microbiol Trop Dis* 2023;9(2):133-134.